טוען...
Escalation strategies for combination therapy Phase I trials
Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose that does not cause an unacceptable amount of toxicity in the patients. In trials of combination therapies, however, many different dose combinations may have a similar probability of causing a dose-lim...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley & Sons, Ltd
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3573644/ https://ncbi.nlm.nih.gov/pubmed/22411472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pst.1497 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|